What it's actually good for
Alpha-ketoglutarate (AKG) isn't exotic — it's a normal intermediate in the Krebs cycle, the pathway every cell uses to generate energy, and levels decline sharply with age. That decline is the biological rationale for supplementing it: restore a metabolite your body used to make more of. Calcium alpha-ketoglutarate (Ca-AKG) is the calcium salt used in essentially every commercial product and in the human trials that exist.
Ca-AKG's popularity rests almost entirely on one number: an "8-year reduction in biological age," reported in a widely shared 2021 paper and repeated across podcasts, newsletters, and Bryan Johnson's Blueprint protocol, which includes 2g of Ca-AKG in its Longevity Mix. That number is real. The study behind it is not what most people assume.
What the research says
The headline claim (Grade C). The 2021 analysis followed 42 people who were already paying customers of Rejuvant, a Ca-AKG supplement, comparing their DNA-methylation "biological age" before and after 4-10 months of self-directed use. There was no placebo group, no randomization, and no control for who chooses to buy and stick with a longevity supplement in the first place — a population plausibly healthier and more health-engaged than average, which independently correlates with slower measured aging. The trial built to answer this honestly — ABLE, a 120-person, double-blind, placebo-controlled RCT comparing 1g/day of sustained-release Ca-AKG against placebo over 6 months — is registered and running, but its most recent published update (2025) reported only recruitment data. Efficacy results aren't out. Worth noting: that's half the 2g/day dose used in commercial Ca-AKG products, including Rejuvant and Bryan Johnson's Blueprint stack — so even a positive result wouldn't confirm the commercial dose does the same thing.
Bone health (Grade B). The strongest actual RCT evidence for AKG has nothing to do with aging clocks — it's a 2007 trial in 76 postmenopausal women with osteopenia, where 6 months of AKG-calcium reduced the bone-resorption marker CTX by 37% versus calcium alone. Bone mineral density also rose, but the increase wasn't statistically significant between groups. The dose matters here: 6g of AKG per day, three times what's in a typical commercial Ca-AKG product.
Mouse longevity data (Grade C). A 2020 Cell Metabolism study found that a 2%-AKG diet extended median lifespan by roughly 10-17% in aged female mice and meaningfully reduced frailty scores in both sexes — a genuinely interesting result on its own terms. It's also a mouse study; plenty of compounds that extend rodent lifespan haven't translated to humans.
Skin (Grade C). The mechanistic case for a skin benefit comes from a 2007 study showing AKG increased collagen output in cultured human skin cells and reduced UV-induced wrinkling when applied topically to mouse skin. That's cell-culture and topical-mouse evidence, not an oral human supplement trial — a materially different claim than what's implied by taking AKG as a daily pill.
How much, and which form
Commercial products, including Rejuvant and Bryan Johnson's Blueprint stack, use 2g/day of Ca-AKG, typically two 1g sustained-release tablets. That's double the 1g/day dose being tested in the ABLE trial — the placebo-controlled study designed to test the age-reversal claim — so a positive ABLE result wouldn't automatically confirm the commercial dose works the same way. Both doses are also well below the 6g/day used in the one published RCT with a statistically significant result, and no one has tested whether either dose produces that effect. Sustained-release formulations are used to limit GI upset versus a single large dose.
Safety & interactions
AKG is an endogenous metabolite, and the trials that exist — up to 6g/day for 6 months in humans, roughly 18 months at 2% of diet in mice — haven't reported serious adverse effects. Multi-year human safety data doesn't exist yet. The calcium salt adds to your total daily calcium intake, worth factoring in if you're already supplementing calcium or have a history of kidney stones. This is informational, not medical advice — check with a clinician before starting.
How we picked the brand
We picked the product actually connected to the human data: Rejuvant, made by the same company whose customers produced the 2021 biological-age cohort, dosed at the standard commercial 2g/day (double the 1g/day dose used in the ongoing placebo-controlled ABLE trial). Generic Ca-AKG powders sold elsewhere haven't been tested in any of the studies above.